Moreover, TGF-βR ablation using CRISPR/Cas9 technology could improve the antitumor activities of anti-tyrosine kinase-like orphan receptor 1 (ROR1)-CAR-T cells against TNBC (Tang et al., 2020), anti-PSMA CAR-T cells against prostate cancer (Kloss et al., 2018), anti-mesothelin CAR-T cells against ovarian cancers (Tang et al., 2020), and anti-B-cell maturation antigen (BCMA) CAR-T cells against myeloma cells (Welstead et al., 2018). The gene discussed is TNFRSF17; the disease is ovarian cancer.